Pravastatin Sodium Tablet
Product Images NDC 69292-101

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pravastatin Sodium (NDC 69292-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amici Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

101-10 (69292 101 10)

This text provides information about a medication called Pravastatin Sodium Tablets, USP. The National Drug Code (NDC) is 632821010. Pravastatin is a medication commonly used to lower cholesterol levels.*

FDA Label Image

101-50 (69292 101 50)

This text contains a World Health Organization International Nonproprietary Name (INN) code "6925210150" and mentions the drug "Pravastatin Sodium". This is likely information related to a medication.*

FDA Label Image

101-90 (69292 101 90)

FDA Label Image

102-10 (69292 102 10)

This is a description of a medication called Pravastatin Sodium, which comes in tablet form. The National Drug Code (NDC) for this medication is 69292-102-10.*

FDA Label Image

102-50 (69292 102 50)

The text provides information about Pravastatin Sodium Tablets, USP with code NoC: 69292-102-50.*

FDA Label Image

102-90 (69292 102 90)

FDA Label Image

103-10 (69292 103 10)

This is a medication information for Pravastatin Sodium tablets, USP with the National Drug Code (NDC) number 69292-103-0.*

FDA Label Image

103-50 (69292 103 50)

This text provides information about a medication with National Drug Code (NDC) 69292-103-50, which is Pravastatin Sodium Tablets, USP.*

FDA Label Image

103-90 (69292 103 90)

FDA Label Image

104-10 (69292 104 10)

FDA Label Image

104-50 (69292 104 50)

FDA Label Image

104-90 (69292 104 90)

FDA Label Image

Graph-1 (Graph 1)

This is a statistical report showing the proportion of subjects without coronary heart disease death or nonfatal myocardial infarction over time, comparing the placebo group with the pravastatin group. The logrank test yielded a p-value of 0.0001, indicating a significant difference between the survival distributions of the two groups. The graph displays the progression over five years since randomization.*

FDA Label Image

Structure (Structure)

This is not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.